0800 069 9269

Functional Mushroom Research Roundup: What the Latest Studies Show (2024, 2025 and 2026)

Quick Answer

Research into functional mushrooms accelerated significantly in 2024, 2025 and into 2026. Key findings include a September 2025 systematic review confirming Lion’s Mane as effective for neuroprotection, cognitive function, and gut health across five RCTs and 21 additional clinical trials. A February 2026 comprehensive review of Cordyceps militaris in Phytotherapy Research synthesised all in vitro, in vivo, and clinical trial evidence for its immunomodulatory, anti-tumour, and neuroprotective effects. A May 2026 MDPI Molecules review covering Ganoderma lucidum, Cordyceps militaris, Trametes versicolor, and related species confirmed their bioactive compounds across multiple disease models. SporeBuddies stocks a curated range of functional and gourmet mushrooms based on species backed by clinical evidence.

Why This Roundup Exists

The functional mushroom space moves fast. New studies are published monthly across PMC, PubMed, and peer-reviewed nutrition and pharmacology journals. Most consumer-facing content on the topic is written once and never updated, meaning the evidence people rely on is often two to five years out of date.

This roundup does something different. It focuses specifically on research published in 2024 and 2025, summarises what each study actually found, and explains what it means for UK consumers using these products daily. It links directly to source material so you can read the underlying science yourself.

Why This Matters

The volume of functional mushroom research is increasing, but quality varies significantly. Understanding which studies are rigorous and which are preclinical or limited in scope helps you make better decisions about which species to prioritise and what to realistically expect from supplementation.

Section 1: Lion’s Mane Research Update

Systematic Review Confirms Multi-Domain Benefits (September 2025)

The most significant Lion’s Mane publication of 2025 is a comprehensive systematic review published in Frontiers in Nutrition (Menon, Jalal et al., September 2025). The review followed PRISMA guidelines and analysed peer-reviewed studies from January 2000 to June 2024, covering five randomised controlled trials, 15 laboratory studies, three pilot clinical trials, one cohort study, and one case report.

The review concluded that Hericium erinaceus is effective across multiple domains: neuroprotection, cognitive function improvement, cancer prevention, gut health promotion, and the reduction of anxiety and depression symptoms. Read the systematic review on PubMed.

This is the most comprehensive human-evidence summary of Lion’s Mane published to date, and its conclusions are notably stronger than previous narrative reviews.

Erinacines and the Neuroprotective Mechanism (2025)

A dedicated systematic review of erinacines, published in Frontiers in Neuroscience in 2025, examined the specific molecular mechanisms by which Lion’s Mane mycelium compounds produce neurobiological effects. The review confirmed that erinacines are cyathane diterpenoids capable of crossing the blood-brain barrier and stimulating NGF synthesis in the central nervous system. It noted that clinical trials showing cognitive improvements in both younger adults (aged 19 to 45) and older adults (aged over 55) are consistent with the erinacine-mediated NGF mechanism established in preclinical work. Read the erinacines review on PMC.

Narrative Review: Neuroprotective, Anti-Inflammatory and Antimicrobial Properties (April 2025)

A narrative review published in Nutrients (April 2025) confirmed that Lion’s Mane bioactives (polysaccharides, hericenones, erinacines, and phenolic compounds) exhibit antioxidant effects by scavenging reactive oxygen species and inducing endogenous antioxidant enzymes. The review also highlighted the mushroom’s potential as a functional food ingredient for gut health and immune modulation, and summarised its neuroregenerative potential across cognitive and neurological disorder models. Read the review on MDPI Nutrients.

What This Means for UK Consumers

The 2025 evidence base for Lion’s Mane is the strongest in the mushroom’s research history. The cognitive benefits, particularly for older adults with mild cognitive impairment, now have robust multi-trial support. The gut health and anti-inflammatory findings are earlier-stage but consistent across multiple study designs.

SporeBuddies stocks dried Lion’s Mane mushrooms (whole fruiting body, organically grown) and health mushroom tinctures using dual extraction. For a detailed breakdown of how Lion’s Mane tincture is used, dosages, and what to expect, see the Lion’s Mane tincture FAQ.

Section 2: Reishi Research Update

Systematic Review and Meta-Analysis of Clinical Trials (2024 to 2025)

A GRADE-assessed systematic review and meta-analysis published in a PMC-indexed journal (2025) examined the impact of Ganoderma lucidum supplementation across a range of 200 to 11,200mg per day over one to 24-week periods in healthy, at-risk, and chronic disease populations. The review drew on data from EMBASE, PubMed, Web of Science, and Scopus up to August 2024. Significant improvements in BMI, cholesterol (TC), creatinine, and oxidative stress markers were observed in specific subgroups, particularly those receiving lower doses (under 1,400mg per day) or aged under 50. Read the meta-analysis on PMC.

The authors noted that while evidence for certain health outcomes is promising, overall evidence quality across outcomes was rated as very low due to trial design limitations. This is an important and honest finding: Reishi has a strong compound profile and solid mechanistic evidence, but large-scale, high-quality RCTs remain limited.

Stress, Cortisol and Psychological Wellbeing (2024)

A 2024 study published in the International Journal of Medicinal Mushrooms examined the effects of Ganoderma lucidum supplementation on psychological stress and selective fitness parameters in female college students in West Bengal, India. The study found improvements in stress markers and fitness measures compared to the control group. Read the study on PubMed.

This adds to a growing body of evidence for Reishi’s adaptogenic properties, specifically its ability to modulate cortisol-linked stress pathways in clinical populations.

Gut Microbiome Modulation (2025 Prebiotic Study)

A 2025 study published in ScienceDirect investigated the prebiotic activity of whole mushroom powders in colonic simulations. Reishi was one of four species examined. The study found that Reishi has been shown in multiple animal models to provide benefit in hyperlipidaemia, diabetes, and obesity models, and has demonstrated activity related to immune function and sleep promotion. It also noted that several small human trials have shown Reishi modulates intestinal microbiota composition. Read the prebiotic activity study on ScienceDirect.

What This Means for UK Consumers

The 2024 and 2025 Reishi evidence continues to support immune regulation, stress modulation, and gut health as its primary areas of benefit. The honest qualification from the 2025 meta-analysis is worth noting: evidence quality is variable, and Reishi’s full clinical potential remains under-researched relative to its compound profile. What is clear is that no significant safety concerns have been identified in any of the reviewed literature at standard doses.

Browse the functional and gourmet mushrooms range at SporeBuddies for Reishi products.

Section 3: Cordyceps Research Update

Tumour Suppression and Immune Sensitisation (2025 PMC Review)

A 2025 PMC review of edible mushrooms as emerging biofactories for natural therapeutics confirmed that cordycepin from Cordyceps militaris suppresses tumour growth, enhances immune surveillance, and sensitises cancer cells to chemotherapy in preclinical studies. Read the full review on PMC.

This is preclinical evidence rather than clinical trial data, but it supports a mechanistic pathway that explains the immune modulation effects documented in earlier human trials.

Gut Microbiota and Metabolic Benefits (2025 Prebiotic Study)

The same 2025 prebiotic study referenced in the Reishi section (ScienceDirect) examined Cordyceps in detail. The researchers found that Cordyceps polysaccharides modulated gut microbiota composition in multiple animal models, stimulated production of short-chain fatty acids (acetate and butyrate), improved intestinal barrier function, and showed immunoregulatory activity in the intestinal mucosa. Hot water extracts from Cordyceps also inhibited pathogenic bacteria while stimulating beneficial gut bacteria including Bacteroides ovatus and Bifidobacterium longum. Read the study on ScienceDirect.

Energy, VO2max and Exercise Performance: The Established Evidence

The foundational exercise performance data for Cordyceps comes from the Hirsch 2016 trial (4g per day, three weeks, significant VO2max improvement). This study remains the most cited human trial in the Cordyceps endurance literature, and no 2024 or 2025 clinical trial has produced contradictory findings. The 2024 Ontawong randomised controlled trial confirmed Cordyceps immune effects (NK cell activity improvement in healthy adults over eight weeks). Read the Ontawong 2024 study on PubMed.

What This Means for UK Consumers

Cordyceps continues to accumulate evidence across energy metabolism, immune function, and gut health. The 2025 data adds mechanistic depth to existing findings rather than overturning them. The exercise performance evidence (VO2max, time to exhaustion) remains the strongest area of human clinical support.

UK buyers should confirm novel food compliance when purchasing Cordyceps supplements. See our mushroom spore types and UK legality guide for more on how novel food classifications apply to functional species in the UK.

Section 4: Turkey Tail Research Update

Comprehensive Medicinal Review (2024)

A 2024 review article on the medicinal potential of Turkey Tail (Trametes versicolor) published in the South African Journal of Botany provided an updated synthesis of available evidence on PSK, PSP, immune modulation, antitumour activity, and gut prebiotic effects. It confirmed that PSK and PSP activate toll-like receptors and boost natural killer and T-cell activity, and that this mechanism underpins the 30-year track record of PSK in cancer adjuvant therapy in Japan.

Immunomodulatory Effects on Older Adults (2023 PMC, Still Relevant)

A PMC study examining medicinal mushroom extracts from Turkey Tail and a related species on immune cells from older adults found that Turkey Tail extracts exerted differential immunomodulatory effects on aged immune cell populations. This is particularly relevant given that immune senescence (the gradual deterioration of immune function with age) is one of the primary drivers of interest in Turkey Tail supplementation. Read the study on PMC.

Prebiotic Activity Confirmed in Colonic Simulation Study (2025)

The 2025 prebiotic activity study (ScienceDirect) confirmed that Turkey Tail mycelium and fruiting body preparations produced measurable prebiotic effects in colonic fermentation models, promoting short-chain fatty acid production and beneficial microbiome shifts. The authors noted the widest spectrum of microbiome species enhancement was observed in multi-mushroom blends that included Turkey Tail. Read the prebiotic study on ScienceDirect.

What This Means for UK Consumers

Turkey Tail has the most clinical history of any functional mushroom in oncology-adjacent research, and 2024 to 2025 research continues to support its immune modulation and gut health applications. The prebiotic data is particularly interesting for users focused on digestive and microbiome health. UK buyers should note Turkey Tail’s novel food classification when purchasing supplements and confirm supplier compliance.

Cross-Species Findings: What the Latest Multi-Mushroom Research Shows

Several 2024 and 2025 studies examined functional mushrooms as a group rather than individually. Three findings are worth summarising.

Anti-Ageing and Cellular Protection

A 2025 PMC review found that extracts from Lion’s Mane, Reishi, and related species improve fibroblast viability under oxidative stress, decrease reactive oxygen species (ROS), and preserve telomere length. These findings position functional mushrooms as candidates for anti-ageing and cellular protection applications, an area of research that is growing rapidly but remains largely preclinical. Read the review on PMC.

Inflammation and Chronic Disease Management

A 2025 PMC review on medicinal mushrooms as immunotherapeutic agents in chronic inflammation management confirmed that multiple functional species (including Reishi, Lion’s Mane, and Turkey Tail) exert anti-inflammatory effects through distinct but complementary mechanisms. Read the review on PMC.

Functional Mushrooms in Beverages and Nutraceuticals

A July 2025 Frontiers in Cellular and Infection Microbiology review highlighted the growing incorporation of Lion’s Mane, Reishi, Cordyceps, and Turkey Tail into functional beverages and nutraceutical formats. It noted formulation challenges, particularly around the stability of hericenones in liquid formats, and identified the cognitive-enhancing properties of Lion’s Mane as driving demand for brain health beverages targeting ageing populations. Read the beverage and nutraceuticals review on Frontiers.

This is relevant for UK consumers choosing between formats (dried, powder, tincture). Stability of active compounds varies significantly by preparation method, and dual extraction remains the most reliable way to preserve both water-soluble and fat-soluble compound classes.

What the Research Does Not Yet Show

A research roundup should be honest about limitations as well as findings. Here is what the 2024 and 2025 literature does not yet fully establish.

Standardised dosing: No consensus exists on optimal dose across species, formats, and health goals. The 2025 Reishi meta-analysis specifically noted that dose-response relationships remain unstandardised. Most trial protocols use different amounts, making direct comparisons difficult.

Long-term human safety beyond one year: Most clinical trials run for 8 to 24 weeks. Data beyond one year in humans is limited for all four species, though no serious adverse events have been reported in any reviewed trial.

Superiority of one format over another in humans: Preclinical data suggests extraction method significantly affects bioavailability, but head-to-head clinical comparisons of formats (whole powder vs. extract vs. tincture) in humans are rare.

Direct causal evidence for some claimed benefits: Some benefits, particularly in the anti-cancer and anti-ageing space, are supported primarily by preclinical and mechanistic data rather than large human trials. These remain promising but unconfirmed at the clinical level.

Being aware of these limitations does not undermine the case for functional mushrooms. It simply means consumers should use them as health-supporting tools grounded in available evidence, rather than treating individual studies as definitive proof of specific outcomes.

Common Mistakes When Interpreting Functional Mushroom Research

  1. Treating preclinical studies as clinical proof Animal models and cell studies establish mechanisms. They do not confirm that the same effects will occur in humans at comparable doses. Distinguish between preclinical evidence (biologically plausible) and clinical evidence (demonstrated in humans).
  2. Assuming all studies used the same form, a study using mycelium extract is not directly comparable to one using fruiting body powder. Compound profiles, concentrations, and bioavailability vary significantly between forms. Check the methods section before drawing conclusions.
  3. Ignoring study size Several widely cited functional mushroom trials involved 30 to 50 participants. These are promising signal trials, not definitive proof. Weight larger, longer, and better-controlled trials more heavily.
  4. Conflating correlation with causation Observational studies showing that regular functional mushroom consumers have better cognitive scores do not prove the mushrooms caused the improvement. Confounding variables (general dietary quality, health consciousness) are significant.
  5. Dismissing early research because it is not a human trial Mechanistic and preclinical research is a legitimate and necessary first step. The erinacine-NGF mechanism, for example, was established in cell and animal studies before being confirmed in human trials. Early-stage research is worth tracking even when it does not yet constitute clinical proof.
  6. Failing to account for the fruiting body versus mycelium distinction Several studies that reported limited effects used mycelium-on-grain preparations with high starch content. This methodological variable is often under-reported, which can make the evidence appear weaker than it is when fruiting body products are used.

Frequently Asked Questions

Is the research on functional mushrooms considered reliable?

The quality varies significantly by study. Large randomised controlled trials with consistent results (such as the Mori 2009 and Docherty 2023 Lion’s Mane trials) represent reliable evidence. Single small pilot trials, animal studies, and industry-funded studies with conflicts of interest should be interpreted with more caution.

How often does new functional mushroom research come out?

Hundreds of studies are published annually. The PMC and PubMed databases index new functional mushroom research every month. The volume of research has increased substantially since 2020, driven by growing consumer interest and pharmaceutical investment.

Where can I read the original studies?

All studies referenced in this article link directly to PubMed, PMC, or peer-reviewed journal websites. These are free to access via the links in the Research References section below.

Do SporeBuddies products align with the studied forms?

Yes. Where clinical trials specify fruiting body preparations, SporeBuddies products (including dried Lion’s Mane and dual-extract tinctures) use whole fruiting body material rather than mycelium-on-grain. This matters because several negative or inconclusive trials used lower-potency mycelium preparations.

Will you update this roundup with new research?

Yes. This guide is updated as significant new research is published. The last update date is shown at the top of the article.

Explore SporeBuddies’ Functional Mushroom Range

SporeBuddies is rated 4.6 stars on Trustpilot (138+ reviews) and 4.9 stars on Yotpo (190+ reviews).

Have a question about a specific product or study? Call free on 0800 [number]. The SporeBuddies team is happy to help.

Related Guides

Section 5: What 2026 Research Adds

As of June 2026, a small but meaningful body of literature published with 2026 issue dates has emerged. It does not overturn any of the 2024 and 2025 findings. It adds new mechanistic depth and broader clinical context, particularly for Cordyceps and multi-species reviews.

Cordyceps militaris: Most Comprehensive Review to Date (February 2026)

The most significant 2026 publication for this guide is a comprehensive review of Cordyceps militaris published in Phytotherapy Research (Yang, Jin, Jiang et al., February 2026, Vol. 40(2), pp. 635–665). This is the most thorough synthesis of Cordyceps militaris evidence published to date, covering in vitro studies, in vivo animal models, and human clinical trials across its full pharmacological range.

Key conclusions from the review: Cordyceps militaris enhances innate and cell-mediated adaptive immunity under both normal conditions and in immunosuppressed states. The primary active constituents (cordycepin, adenosine, polysaccharides, and carotenoids) each exert distinct immunomodulatory, anti-tumour, antioxidant, anti-diabetic, anti-obesity, and neuroprotective activities. The immunomodulatory effects are the most extensively validated across both preclinical and clinical models. Read the review on PubMed.

This is directly relevant for UK consumers: the review establishes a clear mechanistic basis for the energy, endurance, and immune effects that earlier clinical trials (Hirsch 2016, Ontawong 2024) documented in humans.

Lion’s Mane: Prebiotic and Probiotic Properties Confirmed (2026)

A study published in the International Journal of Medicinal Mushrooms (Vol. 28(2), 2026, Pengpa et al.) investigated the prebiotic effects of crude polysaccharide fractions extracted from Hericium erinaceus on multiple probiotic strains. The study found that the HEP-80 fraction significantly enhanced the growth of all three tested probiotic strains compared to unsupplemented controls. At 50 micrograms per millilitre, HEP-80 increased the adhesion of Lactiplantibacillus plantarum by up to 30%. The extract also demonstrated antioxidant activity (DPPH radical inhibition) and cryoprotective properties, preserving over 70% probiotic survival after 90 days of freeze-dried storage. Read the study on PubMed.

This builds on the 2025 gut microbiome evidence by establishing specific mechanisms through which Lion’s Mane polysaccharides support probiotic populations, not just the microbial community in general.

Medicinal Mushrooms and Cancer: Updated Hallmarks Framework (March 2026)

A narrative review published in Frontiers in Cancer Control and Society (Volume 4, 2026) evaluated clinical evidence for medicinal mushrooms in oncology, with specific focus on immunological modulation, treatment tolerability, safety, and integration with chemotherapy. The review used Hanahan’s updated 2026 Cancer Hallmarks framework to map mushroom bioactivities to known cancer mechanisms. It covered literature from 2000 to 2026, including clinical trials, cohort studies, systematic reviews, and meta-analyses. Read the review on Frontiers.

The review’s conclusions support the use of mushroom-derived compounds (including PSK from Turkey Tail and polysaccharides from Reishi and Cordyceps) as adjuncts to conventional cancer treatment based on immunomodulatory and chemotherapy-sensitising mechanisms. This aligns with the established 30-year Japanese clinical use of PSK and reinforces the most evidence-backed application for Turkey Tail specifically.

Broader Multi-Species Review (May 2026)

A comprehensive review published in MDPI Molecules (May 2026) covered bioactive compounds, nutritional value, and functional applications for a range of medicinal mushroom species including Ganoderma lucidum, Cordyceps militaris, Trametes versicolor, and Lentinula edodes. The review noted that clinical research has evaluated safety and therapeutic benefits of medicinal mushroom preparations across multiple disease models, and that research output in the field continues to grow substantially year-on-year. Read the review on MDPI Molecules.

What the 2026 Literature Confirms

Three themes run through all 2026 publications reviewed here:

Cordyceps militaris is the most commercially relevant species for immunity and energy, with a now-comprehensive evidence base across all research tiers (in vitro, in vivo, clinical).

Lion’s Mane gut-brain axis research is maturing, moving from general microbiome modulation findings to specific probiotic interaction mechanisms that link the gut and cognitive effects.

Multi-species frameworks are becoming standard, with researchers now mapping mushroom compounds against cancer hallmarks, inflammation pathways, and metabolic disease models simultaneously rather than treating species in isolation.

The 2026 evidence does not create new reasons for caution. No safety signals have emerged in any of the reviewed publications. The picture of functional mushrooms as broadly safe, multi-mechanism wellness compounds with a growing body of clinical support continues to strengthen.

About This Guide

This research roundup is produced and maintained by the team at SporeBuddies, the UK’s leading specialist supplier of functional mushrooms, mushroom grow kits, mycology supplies, and research-grade spores. All referenced studies are linked directly to their source. No editorial conclusions have been drawn beyond what the cited research supports.

This guide is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before beginning any supplementation protocol.

Share the Post: